Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer
Trial Name: A Phase III, Randomized Clinical Trial of Standard, Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer With Recurrence Score (RS) of 25 Or Less.
Protocol ID: S1007
Enrollment: • About 4,000 women will take part in this study at several medical centers. We expect that about 8,800 women may be tested to see if they can take part, and that about 600 women may have already received the testing before they learn about this clinical trial.
Taking part in this study may or may not make your health better. While doctors hope that the Oncotype DX® test will improve the effectiveness of cancer treatment decision-making compared to the usual methods of deciding treatment, there is no proof of this yet. We do know that the information from this study will help doctors learn more about the use of the Oncotype DX® test in relation to understanding the risk of breast cancer recurrence. This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.
Created: Aug 17, 2011
Updated: May 21, 2014